{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:51:38Z","timestamp":1785333098208,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003010","name":"Ege \u00dcniversitesi","doi-asserted-by":"publisher","award":["TLP-2021-23416"],"award-info":[{"award-number":["TLP-2021-23416"]}],"id":[{"id":"10.13039\/501100003010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11618-z","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:34:00Z","timestamp":1772609640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["BET inhibition enhances temozolomide sensitivity in cervical cancer cells through ALDH suppression and epigenetic reprogramming"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4916-5128","authenticated-orcid":false,"given":"Kemal","family":"Eker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1590-4833","authenticated-orcid":false,"given":"Maryam","family":"Sabour Takanlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6361-7150","authenticated-orcid":false,"given":"Leila","family":"Sabour Takanlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4336-562X","authenticated-orcid":false,"given":"Arman","family":"Rostamlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-4520","authenticated-orcid":false,"given":"Cigir","family":"Biray Avci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"6","key":"11618_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"11618_CR2","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.biopha.2017.10.076","volume":"97","author":"G Sir","year":"2018","unstructured":"Sir G et al (2018) Antagonistic Effect of Oxytocin and Tacrolimus Combination on Adipose Tissue - Derived Mesenchymal Stem Cells: Antagonistic effect of oxytocin and tacrolimus. Biomed Pharmacother 97:1173\u20131181","journal-title":"Biomed Pharmacother"},{"issue":"7623","key":"11618_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/bmj.39337.615197.80","volume":"335","author":"P Petignat","year":"2007","unstructured":"Petignat P, Roy M (2007) Diagnosis and management of cervical cancer. BMJ 335(7623):765\u2013768","journal-title":"BMJ"},{"issue":"12","key":"11618_CR4","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/S0025-6196(11)61104-X","volume":"82","author":"HJ Long","year":"2007","unstructured":"Long HJ 3rd, Laack NN, Gostout BS (2007) Prevention, diagnosis, and treatment of cervical cancer. Mayo Clin Proc 82(12):1566\u20131574","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"11618_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1245\/s10434-015-4555-7","volume":"23","author":"Q Xie","year":"2016","unstructured":"Xie Q et al (2016) Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy. Ann Surg Oncol 23(1):163\u2013170","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"11618_CR6","first-page":"69","volume":"25","author":"C Yu","year":"2011","unstructured":"Yu C et al (2011) ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines. Vivo 25(1):69\u201376","journal-title":"Vivo"},{"issue":"1","key":"11618_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10549-011-1692-y","volume":"133","author":"AK Croker","year":"2012","unstructured":"Croker AK, Allan AL (2012) Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44\u207a human breast cancer cells. Breast Cancer Res Treat 133(1):75\u201387","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"11618_CR8","doi-asserted-by":"publisher","first-page":"e78130","DOI":"10.1371\/journal.pone.0078130","volume":"8","author":"SK Kim","year":"2013","unstructured":"Kim SK et al (2013) Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells. PLoS ONE 8(10):e78130","journal-title":"PLoS ONE"},{"issue":"1","key":"11618_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10654-013-9863-2","volume":"29","author":"E Leoncini","year":"2014","unstructured":"Leoncini E et al (2014) Adult height and head and neck cancer: a pooled analysis within the INHANCE Consortium. Eur J Epidemiol 29(1):35\u201348","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"11618_CR10","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1158\/1541-7786.MCR-08-0035","volume":"6","author":"S Ma","year":"2008","unstructured":"Ma S et al (2008) Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 6(7):1146\u20131153","journal-title":"Mol Cancer Res"},{"issue":"11","key":"11618_CR11","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1158\/0008-5472.CAN-10-3175","volume":"71","author":"IA Silva","year":"2011","unstructured":"Silva IA et al (2011) Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 71(11):3991\u20134001","journal-title":"Cancer Res"},{"issue":"2","key":"11618_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1158\/1055-9965.EPI-09-0865","volume":"19","author":"Y Su","year":"2010","unstructured":"Su Y et al (2010) Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 19(2):327\u2013337","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1\u20133","key":"11618_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cbi.2008.09.029","volume":"178","author":"D Ucar","year":"2009","unstructured":"Ucar D et al (2009) Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 178(1\u20133):48\u201355","journal-title":"Chem Biol Interact"},{"issue":"8","key":"11618_CR14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3174\/ajnr.A2170","volume":"31","author":"JR Wesolowski","year":"2010","unstructured":"Wesolowski JR, Rajdev P, Mukherji SK (2010) Temozolomide (Temodar). AJNR Am J Neuroradiol 31(8):1383\u20131384","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"11618_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1186\/s12885-020-07337-8","volume":"20","author":"T Yao","year":"2020","unstructured":"Yao T et al (2020) ALDH-1-positive cells exhibited a radioresistant phenotype that was enhanced with hypoxia in cervical cancer. BMC Cancer 20(1):891","journal-title":"BMC Cancer"},{"issue":"12","key":"11618_CR16","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/neuonc\/nos270","volume":"14","author":"A Sch\u00e4fer","year":"2012","unstructured":"Sch\u00e4fer A et al (2012) Aldehyde dehydrogenase 1A1\u2013a new mediator of resistance to temozolomide in glioblastoma. Neuro Oncol 14(12):1452\u20131464","journal-title":"Neuro Oncol"},{"key":"11618_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2017.12.036","volume":"417","author":"W Wu","year":"2018","unstructured":"Wu W et al (2018) Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells. Cancer Lett 417:112\u2013123","journal-title":"Cancer Lett"},{"issue":"3","key":"11618_CR18","doi-asserted-by":"publisher","first-page":"100748","DOI":"10.1016\/j.tranon.2020.100748","volume":"13","author":"W Wu","year":"2020","unstructured":"Wu W et al (2020) Lipid Peroxidation Plays an Important Role in Chemotherapeutic Effects of Temozolomide and the Development of Therapy Resistance in Human Glioblastoma. Transl Oncol 13(3):100748","journal-title":"Transl Oncol"},{"issue":"21","key":"11618_CR19","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.1158\/0008-5472.CAN-16-0854","volume":"76","author":"Y Yokoyama","year":"2016","unstructured":"Yokoyama Y et al (2016) BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Res 76(21):6320\u20136330","journal-title":"Cancer Res"},{"issue":"9","key":"11618_CR20","first-page":"491","volume":"73","author":"X Shi","year":"2018","unstructured":"Shi X et al (2018) JQ1: a novel potential therapeutic target. Pharmazie 73(9):491\u2013493","journal-title":"Pharmazie"},{"issue":"3","key":"11618_CR21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.ygyno.2020.06.484","volume":"158","author":"E Bonazzoli","year":"2020","unstructured":"Bonazzoli E et al (2020) Derangements in HUWE1\/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. Gynecol Oncol 158(3):769\u2013775","journal-title":"Gynecol Oncol"},{"issue":"3","key":"11618_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ygyno.2005.09.040","volume":"100","author":"AD Santin","year":"2006","unstructured":"Santin AD et al (2006) HPV16\/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 100(3):469\u2013478","journal-title":"Gynecol Oncol"},{"issue":"7","key":"11618_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1634\/theoncologist.2012-0455","volume":"18","author":"EJ Nam","year":"2013","unstructured":"Nam EJ et al (2013) Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks. Oncologist 18(7):843\u2013849","journal-title":"Oncologist"},{"issue":"4","key":"11618_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41556-020-0491-2","volume":"22","author":"J Nishida","year":"2020","unstructured":"Nishida J et al (2020) Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis. Nat Cell Biol 22(4):465\u2013475","journal-title":"Nat Cell Biol"},{"issue":"15","key":"11618_CR25","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1038\/s41388-021-01735-3","volume":"40","author":"M Ni","year":"2021","unstructured":"Ni M et al (2021) BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. Oncogene 40(15):2711\u20132724","journal-title":"Oncogene"},{"issue":"400","key":"11618_CR26","doi-asserted-by":"publisher","first-page":"eaal1645","DOI":"10.1126\/scitranslmed.aal1645","volume":"9","author":"L Yang","year":"2017","unstructured":"Yang L et al (2017) Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 9(400):eaal1645 https:\/\/doi.org\/10.1126\/scitranslmed.aal1645","journal-title":"Sci Transl Med"},{"key":"11618_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2019.11.017","volume":"126","author":"T Bagratuni","year":"2020","unstructured":"Bagratuni T et al (2020) JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK\/STAT signalling pathway in ovarian cancer. Eur J Cancer 126:125\u2013135","journal-title":"Eur J Cancer"},{"issue":"9","key":"11618_CR28","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/ijc.31986","volume":"144","author":"O Rataj","year":"2019","unstructured":"Rataj O et al (2019) Brd4 inhibition suppresses HPV16 E6 expression and enhances chemoresponse: A potential new target in cervical cancer therapy. Int J Cancer 144(9):2330\u20132338","journal-title":"Int J Cancer"},{"issue":"7327","key":"11618_CR29","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P et al (2010) Selective inhibition of BET bromodomains. Nature 468(7327):1067\u20131073","journal-title":"Nature"},{"issue":"6","key":"11618_CR30","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1021\/acs.nanolett.0c04402","volume":"21","author":"Y Wang","year":"2021","unstructured":"Wang Y et al (2021) Synergistic Therapy for Cervical Cancer by Codelivery of Cisplatin and JQ1 Inhibiting Plk1-Mutant Trp53 Axis. Nano Lett 21(6):2412\u20132421","journal-title":"Nano Lett"},{"issue":"12","key":"11618_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41419-019-2120-1","volume":"10","author":"M \u010can\u010der","year":"2019","unstructured":"\u010can\u010der M et al (2019) BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells. Cell Death Dis 10(12):881","journal-title":"Cell Death Dis"},{"issue":"2","key":"11618_CR32","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1111\/jcmm.14857","volume":"24","author":"G Carr\u00e0","year":"2020","unstructured":"Carr\u00e0 G et al (2020) Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia. J Cell Mol Med 24(2):1650\u20131657","journal-title":"J Cell Mol Med"},{"issue":"11","key":"11618_CR33","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.18632\/oncotarget.1534","volume":"4","author":"A Henssen","year":"2013","unstructured":"Henssen A et al (2013) BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 4(11):2080\u20132095","journal-title":"Oncotarget"},{"issue":"5","key":"11618_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41419-020-2507-z","volume":"11","author":"K Zhang","year":"2020","unstructured":"Zhang K et al (2020) A novel function of IMPA2, plays a tumor-promoting role in cervical cancer. Cell Death Dis 11(5):371","journal-title":"Cell Death Dis"},{"issue":"18","key":"11618_CR35","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.3390\/ijms21186873","volume":"21","author":"HY Cho","year":"2020","unstructured":"Cho HY et al (2020) Combination of ACY-241 and JQ1 synergistically suppresses metastasis of HNSCC via regulation of MMP-2 and MMP-9. Int J Mol Sci 21(18):6873 https:\/\/doi.org\/10.3390\/ijms21186873","journal-title":"Int J Mol Sci"},{"issue":"2","key":"11618_CR36","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/ijms21020665","volume":"21","author":"YW Yi","year":"2020","unstructured":"Yi YW et al (2020) Advances in Analysis of Biodistribution of Exosomes by Molecular Imaging. Int J Mol Sci 21(2):665","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11618_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04315-4","volume":"9","author":"FC Lam","year":"2018","unstructured":"Lam FC et al (2018) Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun 9(1):1991","journal-title":"Nat Commun"},{"issue":"3","key":"11618_CR38","first-page":"153","volume":"40","author":"I Cherciu","year":"2014","unstructured":"Cherciu I et al (2014) Stem cells, colorectal cancer and cancer stem cell markers correlations. Curr Health Sci J 40(3):153\u2013161","journal-title":"Curr Health Sci J"},{"issue":"7","key":"11618_CR39","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/0008-5472.CAN-14-1924","volume":"75","author":"M Cojoc","year":"2015","unstructured":"Cojoc M et al (2015) Aldehyde Dehydrogenase Is Regulated by \u03b2-Catenin\/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. Cancer Res 75(7):1482\u20131494","journal-title":"Cancer Res"},{"issue":"3","key":"11618_CR40","doi-asserted-by":"publisher","first-page":"188894","DOI":"10.1016\/j.bbcan.2023.188894","volume":"1878","author":"H Liu","year":"2023","unstructured":"Liu H et al (2023) Advances in epigenetic modifications and cervical cancer research. Biochim Biophys Acta Rev Cancer 1878(3):188894","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"21","key":"11618_CR41","doi-asserted-by":"publisher","first-page":"10999","DOI":"10.1128\/JVI.00160-11","volume":"85","author":"PL Hyland","year":"2011","unstructured":"Hyland PL et al (2011) Evidence for alteration of EZH2, BMI1, and KDM6A and epigenetic reprogramming in human papillomavirus type 16 E6\/E7-expressing keratinocytes. J Virol 85(21):10999\u201311006","journal-title":"J Virol"},{"issue":"5","key":"11618_CR42","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/1440-1681.12382","volume":"42","author":"M Ding","year":"2015","unstructured":"Ding M et al (2015) The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer. Clin Exp Pharmacol Physiol 42(5):458\u2013464","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"11618_CR43","first-page":"p5555452","volume":"2021","author":"L Zeng","year":"2021","unstructured":"Zeng L, Chen C, Yao C (2021) Histone Deacetylation Regulated by KDM1A to Suppress DACT1 in Proliferation and Migration of Cervical Cancer. Anal Cell Pathol (Amst) 2021:p5555452","journal-title":"Anal Cell Pathol (Amst)"},{"issue":"3","key":"11618_CR44","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1002\/jcp.27080","volume":"234","author":"R Ou","year":"2019","unstructured":"Ou R et al (2019) HPV16 E7-induced upregulation of KDM2A promotes cervical cancer progression by regulating miR-132-radixin pathway. J Cell Physiol 234(3):2659\u20132671","journal-title":"J Cell Physiol"},{"issue":"1","key":"11618_CR45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13148-021-01224-0","volume":"14","author":"J Loaeza-Loaeza","year":"2022","unstructured":"Loaeza-Loaeza J et al (2022) The CpG island methylator phenotype increases the risk of high-grade squamous intraepithelial lesions and cervical cancer. Clin Epigenetics 14(1):4","journal-title":"Clin Epigenetics"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11618-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11618-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11618-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:02:07Z","timestamp":1772614927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11618-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11618"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11618-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"457"}}